A Phase 3 interventional study of TAS-102 and Placebo in Refractory Metastatic Gastric Cancer, sponsored by Taiho Oncology, Inc.. Completed at 139 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-03.
Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Stomach Neoplasms by Otsuka Holdings Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Stomach Neoplasms · Otsuka Holdings Co., Ltd..
Among the 14 studies in Stomach Neoplasms by Otsuka Holdings Co., Ltd., this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2016, is one of 8 in phase 3, and was the 12th registered.
3,404 studies on the registry are indexed under Stomach Neoplasms; 996 are open to participants now.
Browse Stomach Neoplasms studies →1 of the 14 studies in Stomach Neoplasms by Otsuka Holdings Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:
Taiho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 705 Stomach Neoplasms studies recruiting now, 377 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 8
First in 1997; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 507 is above the median of 66 across 2,503 interventional studies indexed under Stomach Neoplasms.
Median enrollment 407 across the 13 interventional studies. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Taiho Oncology, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Taiho Oncology, Inc. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 13 (52%) have results posted.
1 of the studies in Stomach Neoplasms by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04999761Taiho Pharmaceutical Co., Ltd.AB122 Platform Study | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Stomach Neoplasms by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer.
This is a multinational, double-blind, two-arm, parallel, randomized, Phase 3 study evaluating the efficacy and safety of TAS-102 plus BSC versus placebo plus BSC in participants with metastatic gastric cancer who have previously received at least 2 prior regimens for advanced disease. Eligible participants will be centrally randomized (2:1) to TAS-102 + BSC (experimental arm) or placebo + BSC (control arm).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 35 milligrams per meter square (mg/m\^2) of TAS-102 tablets orally twice daily (BID) for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until a discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
Drug: TAS-102
Participants received 35 mg/m\^2 of matching placebo for TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
Drug: Placebo
35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants without documented death were censored at last follow-up or cut-off date, whichever comes first. OS was estimated by Kaplan-Meier method.
Time frame: From the date of randomization to the data cut-off date (maximum duration: up to approximately 46 months)
Progression-Free Survival (PFS)
PFS was defined as the time from randomization until the date of first occurrence of investigator-assessed radiological disease progression or death due to any cause, whichever came first. Disease progression as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) for target lesions were defined as target lesions with at least 20 % relative increase in the sum of diameters with reference to the smallest sum on study, including the baseline sum and this sum demonstrated an absolute increase of at least 5 millimeter (mm) or the appearance of one or more new lesions or Unequivocal progression of existing non-target lesions. All alive participants with no disease progression as of the analysis cut-off date were censored at the last tumor assessment. PFS was estimated by Kaplan-Meier method.
Time frame: From the date of randomization to the cut-off date (maximum duration: up to approximately 46 months)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)
Any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study medication was considered an adverse event (AE). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs/TESAEs were defined as events that started on or after treatment or started before treatment and worsened after the start of treatment through 30 days after the last dose of study treatment.
Time frame: From the first dose of study treatment until 30 days after the last dose of study treatment (maximum duration: up to approximately 46 months)
Overall Response Rate (ORR)
Overall response rate was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR). CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to \< 10 mm. PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference.
Time frame: From the date of randomization to the cut-off date (maximum duration: up to approximately 46 months), assessed every 8 weeks
Disease Control Rate (DCR)
DCR was defined as the proportion of participants with a best overall response of complete response (CR), partial response (PR), or stable disease (SD). The assessment of DCR was based on Investigator review of radiologic images and following RECIST criteria (version 1.1, 2009).
Time frame: From the date of randomization to the cut-off date (maximum duration: up to approximately 46 months), assessed every 8 weeks
Time to Deterioration of European Cooperative Oncology Group (ECOG) Performance Status Score From Baseline
The ECOG performance status was used to evaluate participant's disease progression and the effect of the disease on the participant's activities of daily living. It ranges on the scale from 0-5 (0 = normal activity; 1= symptoms but ambulatory; 2= in bed for \< 50% of the time; 3= in bed for \> 50% of the time; 4= 100% bedridden; 5= dead). Time to definitive deterioration in ECOG performance status score from baseline was defined as a change from 0, 1 to \>=2, or from 2 to \>=3.
Time frame: At the time of randomization (Day 1 Cycle 1) and within 24 hours prior to start of study treatment in every cycle (maximum duration: up to approximately 46 months)
Change From Baseline in Quality of Life European Organization for Research and Treatment for Cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30 Score): Global Health Status
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) and other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health and QoL, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 and 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best QoL for participant.
Time frame: Baseline, Day 1 Cycle 2 up to end of treatment (EOT) (within 30 days of last study treatment) and 30-Day safety follow-up visit (maximum duration: up to approximately 46 months)
EORTC Quality of Life Questionnaire - Gastric-specific Module (EORTC QLQ-STO22): Percentage of Participants With Overall Compliance
The Quality of Life Questionnaire Stomach Cancer Module 22 (QLQ-STO22) assessed symptoms and treatment-related side effects commonly reported in participants. There are 22 questions which comprise 5 scales (dysphagia, dietary restrictions, pain QS22, reflux, and anxiety) and 4 single items (dry mouth, hair loss, taste problems, body image). Most questions use 4-point scale (1='Not at all', 2=a little, 3=quite a bit and 4='Very much'). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100, where higher score=better level of functioning or greater degree of symptoms.
Time frame: Baseline, Cycle 1 Day 1 up to end of treatment (EOT) (within 30 days of last study treatment) (maximum duration: up to approximately 46 months)
The study was conducted at study centers in 17 countries. Participants were involved in the study from 24 February 2016 to 19 December 2019.
| Milestone | TAS-102+BSC | Placebo+BSC |
|---|---|---|
| Started | 337 | 170 |
| As-treated (at) population | 335 | 168 |
| Completed | 0 | 0 |
| Not completed | 337 | 170 |
| Withdrew: Randomized, but not treated | 2 | 2 |
| Withdrew: Ongoing at date of cut-off | 19 | 3 |
| Withdrew: Adverse event | 33 | 11 |
| Withdrew: Clinical progression | 54 | 35 |
| Withdrew: Radiological progression | 192 | 110 |
| Withdrew: Physician's decision | 11 | 3 |
| Withdrew: Withdrawal by subject | 14 | 4 |
| Withdrew: Death | 11 | 2 |
| Withdrew: Protocol deviation | 1 | 0 |
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants without documented death were censored at last follow-up or cut-off date, whichever comes first. OS was estimated by Kaplan-Meier method.
| months | TAS-102+BSC | Placebo+BSC |
|---|---|---|
| Overall Survival (OS) | 5.7 (4.8 to 6.2) | 3.6 (3.1 to 4.1) |
PFS was defined as the time from randomization until the date of first occurrence of investigator-assessed radiological disease progression or death due to any cause, whichever came first. Disease progression as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) for target lesions were defined as target lesions with at least 20 % relative increase in the sum of diameters with reference to the smallest sum on study, including the baseline sum and this sum demonstrated an absolute increase of at least 5 millimeter (mm) or the appearance of one or more new lesions or Unequivocal progression of existing non-target lesions. All alive participants with no disease progression as of the analysis cut-off date were censored at the last tumor assessment. PFS was estimated by Kaplan-Meier method.
| months | TAS-102+BSC | Placebo+BSC |
|---|---|---|
| Progression-Free Survival (PFS) | 2.0 (1.9 to 2.3) | 1.8 (1.7 to 1.9) |
Any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study medication was considered an adverse event (AE). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs/TESAEs were defined as events that started on or after treatment or started before treatment and worsened after the start of treatment through 30 days after the last dose of study treatment.
| Participants | TAS-102+BSC | Placebo+BSC |
|---|---|---|
| TEAE | 319 | 151 |
| TESAE | 143 | 70 |
Overall response rate was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR). CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to \< 10 mm. PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference.
| percentage of participants | TAS-102+BSC | Placebo+BSC |
|---|---|---|
| Overall Response Rate (ORR) | 4.5 (2.4 to 7.5) | 2.1 (0.4 to 5.9) |
DCR was defined as the proportion of participants with a best overall response of complete response (CR), partial response (PR), or stable disease (SD). The assessment of DCR was based on Investigator review of radiologic images and following RECIST criteria (version 1.1, 2009).
| percentage of participants | TAS-102+BSC | Placebo+BSC |
|---|---|---|
| Disease Control Rate (DCR) | 44.1 (38.3 to 50.1) | 14.5 (9.2 to 21.3) |
The ECOG performance status was used to evaluate participant's disease progression and the effect of the disease on the participant's activities of daily living. It ranges on the scale from 0-5 (0 = normal activity; 1= symptoms but ambulatory; 2= in bed for \< 50% of the time; 3= in bed for \> 50% of the time; 4= 100% bedridden; 5= dead). Time to definitive deterioration in ECOG performance status score from baseline was defined as a change from 0, 1 to \>=2, or from 2 to \>=3.
| months | TAS-102+BSC | Placebo+BSC |
|---|---|---|
| Time to Deterioration of European Cooperative Oncology Group (ECOG) Performance Status Score From Baseline | 4.3 (3.7 to 4.7) | 2.3 (2.0 to 2.8) |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) and other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health and QoL, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 and 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best QoL for participant.
| units on a scale | TAS-102+BSC | Placebo+BSC |
|---|---|---|
| Cycle 1 | -2.7 ± 17.56 | -5.9 ± 22.20 |
| Cycle 2 | -5.9 ± 20.51 | -7.3 ± 25.80 |
| Cycle 3 | -4.1 ± 18.26 | -1.4 ± 22.00 |
| Cycle 4 | -3.6 ± 17.54 | -1.7 ± 22.32 |
| Cycle 5 | -5.9 ± 18.05 | 11.1 ± 18.16 |
| Cycle 6 | -8.8 ± 23.05 | 15.6 ± 21.10 |
| Cycle 7 | -9.5 ± 21.96 | 20.0 ± 4.56 |
| Cycle 8 | -4.3 ± 23.82 | 16.7 ± 11.79 |
| Cycle 9 | 2.4 ± 17.12 | 16.7 ± 16.67 |
| Cycle 10 | -14.4 ± 25.57 | 25.0 ± 11.79 |
| Cycle 11 | -16.7 ± 37.27 | 25.0 ± 11.79 |
| Cycle 12 | -8.3 ± 11.79 | 33.3 |
| Cycle 13 | 0.0 | 33.3 |
| Cycle 14 | — | 33.3 |
| Cycle 15 | — | 33.3 |
| Last Collection Cycle | -8.8 ± 20.91 | -9.8 ± 25.34 |
| Safety Follow-Up | -16.5 ± 23.45 | -8.9 ± 18.33 |
The Quality of Life Questionnaire Stomach Cancer Module 22 (QLQ-STO22) assessed symptoms and treatment-related side effects commonly reported in participants. There are 22 questions which comprise 5 scales (dysphagia, dietary restrictions, pain QS22, reflux, and anxiety) and 4 single items (dry mouth, hair loss, taste problems, body image). Most questions use 4-point scale (1='Not at all', 2=a little, 3=quite a bit and 4='Very much'). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100, where higher score=better level of functioning or greater degree of symptoms.
| percentage of participants | TAS-102+BSC | Placebo+BSC |
|---|---|---|
| Dysphagia | 86.6 | 78.2 |
| Dietary Restrictions | 86.6 | 78.2 |
| Pain QS22 | 86.6 | 78.2 |
| Reflux | 86.6 | 78.2 |
| Anxiety | 86.6 | 78.2 |
| Dry Mouth | 86.4 | 78.2 |
| Body Image | 85.8 | 78.2 |
| Hair Loss | 86.6 | 78.2 |
| Taste Problems | 86.6 | 78.2 |
Collected over From first dose of study treatment up to 30 days of last study treatment (maximum duration: up to approximately 46 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAS-102+BSC | 252/335 (75.2%) | 143/335 (42.7%) | 319/335 (95.2%) |
| Placebo+BSC | 141/168 (83.9%) | 70/168 (41.7%) | 151/168 (89.9%) |
| Event | TAS-102+BSC | Placebo+BSC |
|---|---|---|
| General physical health deteriorationGeneral disorders | 21/335 | 15/168 |
| AscitesGastrointestinal disorders | 3/335 | 7/168 |
| AnaemiaBlood and lymphatic system disorders | 13/335 | 4/168 |
| Abdominal painGastrointestinal disorders | 8/335 | 6/168 |
| Decreased appetiteMetabolism and nutrition disorders | 11/335 | 4/168 |
| VomitingGastrointestinal disorders | 9/335 | 1/168 |
| PancytopeniaBlood and lymphatic system disorders | 7/335 | 0/168 |
| DiarrhoeaGastrointestinal disorders | 6/335 | 0/168 |
| DysphagiaGastrointestinal disorders | 6/335 | 2/168 |
| Gastric haemorrhageGastrointestinal disorders | 3/335 | 3/168 |
| Event | TAS-102+BSC | Placebo+BSC |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 142/335 | 30/168 |
| NeutropeniaBlood and lymphatic system disorders | 128/335 | 6/168 |
| NauseaGastrointestinal disorders | 123/335 | 53/168 |
| Decreased appetiteMetabolism and nutrition disorders | 109/335 | 49/168 |
| FatigueGeneral disorders | 87/335 | 35/168 |
| VomitingGastrointestinal disorders | 80/335 | 34/168 |
| AstheniaGeneral disorders | 65/335 | 37/168 |
| DiarrhoeaGastrointestinal disorders | 73/335 | 24/168 |
| LeukopeniaBlood and lymphatic system disorders | 57/335 | 3/168 |
| Abdominal painGastrointestinal disorders | 50/335 | 27/168 |
Analysis was performed on the Intent-to-Treat (ITT) population that included all randomized participants, regardless of whether or not study treatment was administered.
| Age, Continuous(Years) | TAS-102+BSC | Placebo+BSC | Total |
|---|---|---|---|
| Mean | 62.8 ± 10.78 | 62.0 ± 10.04 | 62.5 ± 10.53 |
| Sex: Female, Male(Participants) | TAS-102+BSC | Placebo+BSC | Total |
|---|---|---|---|
| Female | 85 | 53 | 138 |
| Male | 252 | 117 | 369 |
| Race/Ethnicity, Customized(Participants) | TAS-102+BSC | Placebo+BSC | Total |
|---|---|---|---|
| White | 244 | 113 | 357 |
| Black/African American | 1 | 2 | 3 |
| Asian | 51 | 29 | 80 |
| Not collectable | 38 | 24 | 62 |
| Other | 3 | 2 | 5 |
| European Cooperative Oncology Group (ECOG) Performance Status(Participants) | TAS-102+BSC | Placebo+BSC | Total |
|---|---|---|---|
| ECOG Grade 0 | 123 | 68 | 191 |
| ECOG Grade 1 | 214 | 102 | 316 |
Showing the first 100 of 139 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2016 to primary completion in Apr 2018, 26 months.
Results were first posted in Sep 2021, 3 years 4 months after primary completion.
Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 26 months is below that.
Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.